A5069230876- Liver Disease and Transplantation
- Organ Transplantation Techniques and Outcomes
- Liver Disease Diagnosis and Treatment
- Renal Transplantation Outcomes and Treatments
- Hepatitis C virus research
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver physiology and pathology
- Hepatitis B Virus Studies
- Neurological Complications and Syndromes
- COVID-19 Clinical Research Studies
- Viral-associated cancers and disorders
- Transplantation: Methods and Outcomes
- Helicobacter pylori-related gastroenterology studies
- Organ Donation and Transplantation
- Liver Diseases and Immunity
- Pancreatic function and diabetes
- Cancer Diagnosis and Treatment
- Metabolism and Genetic Disorders
- Infectious Encephalopathies and Encephalitis
- Herpesvirus Infections and Treatments
- Tissue Engineering and Regenerative Medicine
- Cancer, Lipids, and Metabolism
- COVID-19 epidemiological studies
- Wireless Body Area Networks
- Hepatitis Viruses Studies and Epidemiology
Hospital Universitario Puerta de Hierro Majadahonda
2024
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
2016-2024
Hospital Clínico Universitario Lozano Blesa
2015-2024
Instituto de Investigación Sanitaria Aragón
2014-2024
Hospital Universitario Río Hortega
2022
Centro de Investigación Biomédica en Red
2022
Hospital General Universitario de Alicante Doctor Balmis
2022
Universidad de Zaragoza
2002-2021
Montefiore Medical Center
1998-2021
Hospital Universitario Virgen del Rocío
2021
Antiviral prophylaxis is recommended in cytomegalovirus (CMV)-seropositive kidney transplant (KT) recipients receiving antithymocyte globulin (ATG) as induction. An alternative strategy of premature discontinuation after CMV-specific cell-mediated immunity (CMV-CMI) recovery (immunoguided prevention) has not been studied. Our aim was to determine whether it effective and safe discontinue when CMV-CMI detected continue with preemptive therapy.In this open-label, noninferiority clinical trial,...
Graphical Abstract
Cardiovascular (CV) diseases are recognized longterm causes of death after liver transplantation (LT). The objective this multicenter study was to analyze the prevalence and evolution CV risk factors morbidity mortality in 1819 LT recipients along 5 years LT. influence baseline variables on survival, morbidity, studied. There a continuous significant increase all (except smoking) were fourth cause LT, causing 12% deaths during follow-up. Most events (39%) occurred first year Preexisting such...
Sorafenib (SOR) is the standard of care for patients with hepatocellular carcinoma (HCC) and portal vein invasion (PVI), based on results phase 3 trials. However, radioembolization (RE) using yttrium-90 microspheres has been shown to achieve higher response rates better survival in large cohorts 2 This study aimed compare HCC PVI treated by RE or SOR.Survival among SOR four Spanish hospitals between 2005 2013 was analysed retrospectively. Kaplan-Meier curves were plotted baseline variables...
Frailty is prevalent in liver transplant (LT) candidates. It considered an independent predictor of adverse outcomes pre- and post-transplant according to data obtained the United States. We aimed externally validate frailty index (LFI) a multicenter cohort LT
The impact of donor age on liver transplantation has been analyzed in several studies with contradictory results. Our aim was to evaluate graft survival and complications the first year after transplantations livers from older donors.Prospective analysis 149 consecutive primary performed between 2000 2005. Transplantations were divided into two groups according age: group A, <60 yr old (n=102); B, ≥60 (n=47).Chronic acute rejection, vascular complications, infections not statistically...
// Alberto Lué 1, 2 , Maria Trinidad Serrano Francisco Javier Bustamante 3 Mercedes Iñarrairaegui 4, 5 Juan Ignacio Arenas 6 Milagros Testillano Sara Lorente Cristina Gil Manuel de la Torre 4 Alexandra Gomez and Bruno Sangro 1 Department of Gastroenterology, Hospital Clínico Universitario Lozano Blesa, 50009, Zaragoza, Spain Instituto Investigación Sanitaria (IIS) Aragón, Cruces, Plaza 48903, Barakaldo, Liver Unit, Clinica Universidad Navarra-IDISNA, 31008, Pamplona, Centro Investigacion...
Besides environmental factors, the genetic background of an individual may contribute to development and final outcome peptic ulcer disease. Interleukin-1beta (IL-1beta) interleukin-1 receptor antagonist (IL-1ra) are cytokines that play a key role in modulating inflammatory response gastrointestinal mucosa. This study aimed investigate whether polymorphisms IL-1B IL-RN genes involved susceptibility DNA from 179 unrelated Spanish Caucasian patients with diseases 99 ethnically matched healthy...
A national, multicenter, retrospective study was conducted to assess the results obtained for liver transplant recipients with conversion everolimus in daily practice. The included 477 (481 transplantations). Indications were renal dysfunction (32.6% of cases), hepatocellular carcinoma (HCC; 30.2%; prophylactic treatment 68.9%), and de novo malignancy (29.7%). median time from transplantation 68.7 months malignancy, 23.8 dysfunction, 7.1 HCC other indications. During first year treatment,...
The impact of human immunodeficiency virus (HIV) infection on patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC) is uncertain. This study aimed to assess the outcome a prospective Spanish nationwide cohort HIV-infected LT HCC (2002-2014). These were matched (age, gender, year LT, center, and hepatitis C (HCV) or B infection) with non-HIV-infected controls (1:3 ratio). Patients incidental excluded. Seventy-four 222 included. All had cirrhosis, mostly due HCV...
Direct-acting antivirals have proved to be highly efficacious and safe in monoinfected liver transplant (LT) recipients who experience recurrence of hepatitis C virus (HCV) infection. However, there is a lack data on effectiveness tolerability these regimens HCV/HIV-coinfected patients HCV infection after LT. In this prospective, multicenter cohort study, the outcomes 47 LT received DAA therapy (with or without ribavirin [RBV]) were compared with those matched 148 HCV-monoinfected similar...
Pravastatin has demonstrated anti-tumor activity in preclinical and clinical studies. This multicentric randomized double-blind placebo-controlled phase II study (NCT01418729) investigated the efficacy safety of sorafenib + pravastatin combination on overall survival (OS) time to progression (TTP) patients with advanced hepatocellular carcinoma (aHCC). A total 31 were randomized. Median OS did not differ between both groups (12.4 months for group vs. 11.6 control group). Of note, however,...
The purpose of the study was to build a predictive model for estimating risk ICU admission or mortality among patients hospitalized with COVID-19 and provide user-friendly tool assist clinicians in decision-making process. cohort comprised 3623 confirmed who were SALUD hospital network Aragon (Spain), which includes 23 hospitals, between February 2020 January 2021, period that several pandemic waves. Up 165 variables analysed, including demographics, comorbidity, chronic drugs, vital signs,...